Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 51Endometrial Neoplasms 21Fallopian Tube Neoplasms 17Sarcoma 9Peritoneal Neoplasms 9Neoplasm Metastasis 7Neoplasms 6Liposarcoma 6Leiomyosarcoma 5Hemangiosarcoma 5Fibrosarcoma 5Carcinoma, Ovarian Epithelial 5Uterine Neoplasms 4Stomach Neoplasms 4Sarcoma, Synovial 4Recurrence 4Neurofibrosarcoma 4Malignant mesenchymal tumor 4Histiocytoma, Malignant Fibrous 4Desmoplastic Small Round Cell Tumor 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma, Endometrial Stromal 3Rhabdomyosarcoma 3Hemangiopericytoma, Malignant 3Breast Neoplasms 3Appendiceal Neoplasms 3Sarcoma, Alveolar Soft Part 2Pheochromocytoma 2

Interventions

pembrolizumab 3lenvatinib 2Injections 2anlotinib 1Paclitaxel 1NVP-BKM120 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Endometrial Cancer × Doxorubicin × Gynecologic × Clear all
NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
71 enrolled
GynecologicSarcoma

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡